LINDAHL RICHARD S 4

What Happened
Richard S. Lindahl, Chief Financial Officer of Emergent BioSolutions Inc., was granted 162,680 restricted stock units (RSUs) on April 29, 2026. The Form 4 reports the acquisition price as $0.00 (typical for RSU awards) and lists the transaction as an award rather than a purchase or sale.

Key Details

• Transaction date: 2026-04-29; reported acquisition type: Award (Code A); reported price: $0.00.
• Award size: 162,680 restricted stock units (each RSU represents the right to one share upon vesting).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Approval: Grant was approved by the Compensation Committee on March 2, 2026, subject to and following stockholder approval of an amendment to the 2006 Stock Incentive Plan; stockholders approved the amended plan on April 29, 2026. (See footnotes.)
• Vesting: RSUs vest in three annual installments beginning on the anniversary of the approval date, subject to continued service.
• Filing timeliness: Form 4 filed May 1, 2026, which appears to be within the standard two-business-day reporting window.

Context
This is a compensation award (RSUs), not an open-market buy or sale. RSUs only convert to actual shares (and potential liquidity) as they vest and are typically subject to continued employment and the plan/grant terms. Such grants are common executive compensation and are not by themselves a direct market signal.